Agoracom Blog Home

Posts Tagged ‘small caps’

Renforth Resources Confirms 363,000 Ounces of Gold Beside Canada’s Largest Gold Mine

Posted by Brittany McNabb at 12:25 PM on Thursday, April 17th, 2025

A Major Step Forward for a Junior Explorer With Proven Vision

In a landscape where small-cap mining companies often struggle to produce meaningful results, Renforth Resources (CSE: RFR | OTC: RFHRF | FSE: 9RR) has just delivered a development that could significantly shift its standing in the gold sector.

In an exclusive interview, CEO Nicole Brewster confirmed a 29% increase in the gold resource at the company’s flagship Parbec Gold Deposit in Quebec. This brings the total to 363,000 ounces of gold, of which 265,000 ounces are now classified as Measured and Indicated—a substantial upgrade in confidence and quality. Notably, 12% of the total ounces are in the Measured category, and 87% of the ounces are within a Whittle pit shell, underscoring the deposit’s open-pit viability and potential economic value.

All of this is happening next door to Agnico Eagle’s Canadian Malartic Mine, one of the largest and most productive gold operations in the country.

Why This Matters: Grade, Location, and Optionality

Renforth’s Parbec project lies on the prolific Cadillac Break, a structure responsible for over 100 million ounces of historical gold production in Canada. Yet Parbec is no mere geological curiosity. It is:

  • Surface-exposed and fully road-accessible;
  • Situated beside Canada’s largest open-pit gold mine;
  • Host to infrastructure including a historic underground ramp;
  • Surrounded by multiple toll-milling facilities operated by Agnico Eagle and other major producers;
  • And now, significantly de-risked with its enhanced resource classification.

This strategic location puts Renforth in a rare position to benefit from regional processing demand.

“With this update, 73% of Parbec’s ounces are now in the Measured and Indicated categories,” said Brewster. “We consider Parbec a small-scale replica of Canadian Malartic — same geology, same break, similar surface profile.”

Flexible Pathways to Monetization

Renforth is not committing to a single development path. Instead, it is evaluating a range of monetization options:

  • Sale: Parbec’s location, ounces, and infrastructure make it an ideal bolt-on asset for a producer like Agnico Eagle, whose “fill-the-mill” strategy is now in full swing following acquisitions like the Marban project.
  • Joint Venture: Brewster confirmed the company has received partnership inquiries and could benefit from joint development.
  • Toll Milling / Bulk Sampling: If desired, Renforth could begin small-scale production through existing infrastructure, with low capex and minimal environmental footprint.

Further exploration could still add additional ounces, especially in areas beneath the current pit model and into the Pontiac sediments, where new gold-bearing structures have already been identified.

Macro Tailwinds: Gold’s Rise Aligns With Renforth’s Momentum

The timing of this update couldn’t be more strategic. Gold is trading above $3,200 USD per ounce, and many experts, including Brewster, expect it to remain above $3,000 throughout 2025, driven by central bank buying, geopolitical instability, and inflationary concerns.

Renforth’s latest resource estimate was calculated at $2,100 USD per ounce, suggesting further upside potential if gold prices hold or increase.

Internally, the company has already run sensitivity analyses using higher gold prices, which indicate more ounces could be captured in future updates.

The Bigger Picture: Strategic Fit in a Global Mining Corridor

Renforth’s Parbec project aligns neatly with a growing global emphasis on resource security and domestic development. With Canada reaffirming its role as a stable jurisdiction for mining, and gold once again capturing investor attention, Renforth has a credible, scalable project in a tier-one location.

Add in the exploration upside, established infrastructure, and multiple monetization options, and the result is a company with more than just potential — it has momentum.

Final Thoughts

In an industry where many juniors struggle to translate drill results into real-world opportunity, Renforth Resources has delivered what few others have: a tangible, credible, and increasingly valuable gold asset in one of the world’s most prolific mining jurisdictions.

The 363,000-ounce Parbec resource — 87% of it in an open-pit shell and 265,000 ounces in Measured and Indicated — isn’t just a milestone. It’s a statement.

And as Brewster concluded: “We’re in no rush. Time is on our side — and so is gold.”

Watch the full interview here: 

Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Posted by Brittany McNabb at 11:10 AM on Wednesday, April 16th, 2025

From clinical breakthroughs in multiple sclerosis to a fast-growing alcohol detox brand, Quantum BioPharma is bridging biotech innovation with real-world impact.

A Biopharma Platform Tackling Today’s Toughest Health Challenges

Quantum BioPharma Ltd. (NASDAQ: QNTM | CSE: QNTM) is emerging as a dynamic force in the biotechnology sector, developing solutions for two major public health issues: neurodegenerative diseases and alcohol misuse. With a diversified pipeline spanning prescription drugs and over-the-counter consumer products, the company is building an integrated portfolio capable of delivering both near-term commercial gains and long-term medical breakthroughs.

The company’s strategy is uniquely positioned at the intersection of science, innovation, and unmet need — making it one of the few small-cap biotechs advancing both FDA-bound therapeutics and consumer-ready wellness products simultaneously.

Lucid-MS: Targeting the Root Cause of Multiple Sclerosis

At the heart of Quantum’s pharmaceutical program is Lucid-MS, a patented new chemical entity showing early promise in treating multiple sclerosis (MS). Unlike conventional MS drugs that focus on managing inflammation, Lucid-MS addresses the core driver of long-term disability in MS: the breakdown of the myelin sheath — the protective layer around nerve fibers.

Following a successful Phase 1 clinical trial, the drug has been deemed safe and well-tolerated, with therapeutic blood levels observed in healthy participants. Quantum is now preparing to launch a Phase 2 trial in 2026, targeting efficacy in MS patients.

What makes Lucid-MS even more distinctive is Quantum’s collaborative study with Massachusetts General Hospital (MGH), featuring scientists from Harvard Medical School, to validate advanced PET imaging as a way to monitor demyelination in real time. This partnership elevates both the scientific credibility and clinical precision behind Lucid-MS, positioning it as a next-generation therapeutic candidate in a $27 billion global MS treatment market.

unbuzzd™: A Consumer Wellness Product with Scientific Backing

In parallel with its clinical pipeline, Quantum BioPharma is making significant inroads in the consumer wellness market through unbuzzd™, an over-the-counter alcohol detox and recovery beverage developed by its spinout, Celly Nutrition Corp. The product, a fast-acting powder stick formulated by pharmacology experts, is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

unbuzzd™ is already making retail waves. Backed by a double-blind, placebo-controlled clinical trial, the beverage demonstrated that it could reduce blood alcohol concentration (BAC) over 40% faster than placebo in many subjects. It’s now available via Amazon and unbuzzd.com, with retail expansion underway in the U.S., Puerto Rico, and the Caribbean through a new distribution agreement with FUSION Distribution Group.

Most recently, unbuzzd™ entered a landmark partnership with AATAC, one of the largest retail networks in the U.S., which connects the product to over 80,000 convenience store locations. This expansion gives unbuzzd™ exposure to leading chains like 7-Eleven, Circle K, Shell, and ampm — significantly scaling its retail footprint.

Multiple Value Streams, One Vision

Quantum BioPharma holds 25.71% ownership in Celly Nutrition and receives up to 7% in royalties from unbuzzd™ sales until a $250M threshold is met — and 3% in perpetuity thereafter. This structure offers upside exposure to the high-growth consumer market while maintaining strategic focus on the pharmaceutical pipeline.

With an improved cash position, enhanced operational efficiency, and momentum across both drug development and consumer wellness fronts, the company is now advancing toward key inflection points on multiple fronts.

A Biotech Story Worth Watching

With a first-in-class MS treatment advancing toward Phase 2 trials, a consumer product already on shelves and gaining market traction, and elite partnerships with global institutions like Harvard and AATAC — Quantum BioPharma stands apart in the small-cap biotech landscape.

It’s not just a company developing drugs. It’s building a platform for impact, backed by scientific validation and commercial momentum.


YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

This Small Cap Gold Company Announced 363,000 Ounces As Gold Sets Record Prices

Posted by Brittany McNabb at 4:38 PM on Tuesday, April 15th, 2025

In this interview with AGORACOM, Renforth Resources Inc. (CSE: RFR | OTCQB: RFHRF | FSE: 9RR) CEO Nicole Brewster discusses the company’s newly updated 2025 Mineral Resource Estimate for its 100%-owned Parbec Gold Deposit in Quebec — a move that significantly strengthens the company’s value proposition at a time when gold prices continue to surge. The updated estimate now totals 363,000 ounces of gold, marking a 29% increase over the previous figure and signaling growing maturity and confidence in the deposit. Notably, 265,000 ounces are now categorized as Measured and Indicated, and 87% of the total resource sits within an open pit — directly adjacent to Agnico Eagle’s Canadian Malartic Mine, one of Canada’s largest gold operations.

KEY HIGHLIGHTS: Open Pit Advantage: With mineralization starting at surface and a pit depth of 300 meters, Parbec’s economics are compelling, especially with nearby toll milling options. Strategic Fit for Agnico: The project’s location beside Canadian Malartic and proximity to multiple mills makes it a potential solution for Agnico Eagle’s “fill-the-mill” strategy — especially amid $5.6B in M&A activity in the district.

Clear Monetization Path: CEO Nicole Brewster outlines a three-path strategy: sale, joint venture, or self-development, including a plan to initiate stripping and bulk sampling this summer for potential cash flow.

A COMPELLING QUOTE FROM THE CEO “We are very happy to deliver this significant size increase to our open pit gold deposit next door to Agnico Eagle’s Canadian Malartic mine… With this MRE, 87% of the gold ounces within the resource estimate are contained within the accompanying open pit.” — Nicole Brewster, CEO

WHY INVESTORS SHOULD WATCH THIS INTERVIEW Renforth has done what many small caps struggle to achieve: increase its resource size while also upgrading confidence categories — all while controlling costs and maintaining 100% ownership in one of the world’s top-ranked mining jurisdictions. With strategic positioning next to Canada’s mining giant, viable paths to monetization, and growing relevance in a high-gold-price environment, Parbec is moving from potential to probability.

This interview isn’t just an update — it’s a real-time look into how Renforth is strategically unlocking value from its assets and evaluating serious next steps. Watch the full interview now to understand why Renforth could be a key player in Quebec’s next wave of gold development.

Kidoz Delivers Record Quarter WIth $10.7 Million In Revenue For Q4-24

Posted by Brittany McNabb at 11:04 AM on Thursday, April 10th, 2025

Kidoz Inc. (TSXV: KIDZ), the global leader in child-safe mobile advertising, just posted its strongest quarter to date—solidifying its position as the default monetization platform for digital content aimed at children under 13. 

With quarterly revenue hitting $10.7 million and a pre-tax profit of $2.9 million, the company not only returned to profitability but also showcased the strength of its privacy-first model in a rapidly evolving regulatory environment.

STRATEGIC GROWTH BACKED BY INDUSTRY GIANTS

Kidoz’s impressive growth is underpinned by key partnerships and widespread industry adoption:

  • Integrated into nearly 5,000 kid-focused apps
  • Reaches over 400 million monthly active users globally
  • Trusted by brands like Disney, LEGO, Mattel, McDonald’s, and Hasbro
  • Certified partner of Apple and Google

The company’s AI-powered contextual ad engine, which targets content—not personal behavior—is proving essential as tech platforms introduce tools to support age-appropriate experiences.

THE KID SAFE REGULATORY ADVANTAGE

As lawmakers tighten the rules around data privacy—particularly for children—Kidoz stands apart. The company is fully compliant with global standards like COPPA and GDPR-K and is already aligned with forthcoming legislation like COPPA 2.0, which will mandate age-gating and data separation for under-13 audiences.

“Unlike traditional ad networks, we don’t collect our profile user data. Our contextual AI targeting is designed from the ground up to protect kids’ privacy—and that’s become our biggest competitive advantage.”
— Jason Williams, CEO of Kidoz Inc.

LOOKING AHEAD: PROFITABILITY, SCALE & MARKET SHARE

Kidoz has committed to maintaining quarterly profitability throughout 2025. With regulators enforcing stricter data use policies and major brands seeking safe ad environments, the company is capturing a growing share of a market forecast to surpass $100 billion in digital ad spend.

With a clear regulatory tailwind, scalable technology, and a rapidly growing client base, Kidoz is not just adapting to change—it’s defining the future of child-focused digital advertising.

280,000 Ounces of Gold, Major Critical Minerals & Near $5.5B in M&A: Renforth’s Moment Is Here

Posted by Brittany McNabb at 12:48 PM on Thursday, April 3rd, 2025

Renforth Resources: Positioned for Gold and Critical Mineral Success in Quebec

In a compelling new interview with AGORACOM, Renforth Resources Inc. (CSE: RFR | OTCQB: RFHRF | FSE: 9RR) CEO Nicole Brewster laid out a clear and convincing case for why this Canadian junior exploration company is exceptionally well-positioned amid record gold prices and rising global demand for critical minerals. With flagship assets in Quebec’s world-renowned Abitibi mining district, Renforth is advancing both its 100%-owned Parbec Gold Deposit and the massive Malartic Metals Package — a combined landholding that sits in one of the richest and most active mining corridors in North America.

Strategic Location Beside Mining Giants

Renforth’s Parbec Gold Project is situated directly adjacent to Agnico Eagle’s Canadian Malartic Mine, the country’s largest open-pit gold mine. The deposit already contains 280,000 ounces of gold (101,000 oz indicated, 177,000 oz inferred), with a new NI 43-101 resource estimate expected soon. This update will include 15,000 metres of additional drilling and could significantly increase the gold resource, especially with current gold prices near C$4,500/oz.

The Parbec project benefits from exceptional infrastructure: direct road access, two hydroelectric lines crossing the property, nearby toll milling facilities, and close proximity to the Glencore-owned Horn Smelter. As Brewster puts it, “It can’t get cheaper than this — the economics of development in this region are simply unbeatable.”

Malartic Metals Package: A Critical Mineral Powerhouse

Located just north of Parbec, the 300 km² Malartic Metals Package hosts the emerging 20-kilometre-long Victoria nickel-sulphide polymetallic structure. Recent metallurgical results show that the mineralization — which includes nickel, zinc, copper, cobalt, and silver — is hosted in conventional sulphide minerals, indicating potential for standard, cost-effective processing.

Initial mineralogical analysis and TOMRA sorting tests demonstrate strong early signs of recoverability and grade optimization. Brewster also confirmed that Renforth is working with SGS to determine whether its current drilling supports a maiden resource — an important step toward unlocking value in this new discovery.

In the Midst of $5.6 Billion in M&A

Renforth is surrounded by major mining players. Agnico Eagle has spent billions acquiring and consolidating deposits across the Abitibi in recent years, including the Yamana and O3 Mining deals. Parbec sits right in the middle of this activity, offering both strategic value and expansion potential to any nearby operator looking to sustain mill throughput or grow their regional footprint.

“This is a proven gold deposit, sitting beside a mine that’s going underground and needs more ore. The strategic value is obvious,” Brewster stated.

Quebec Advantage: Cost, Policy, and Market Access

Renforth’s position in Quebec provides significant advantages beyond geology. The province is routinely ranked as a top-tier mining jurisdiction globally, and the Quebec government recently introduced new stimulus programs specifically aimed at accelerating critical mineral exploration. With access to hydroelectric power, deepwater ports, rail lines, and North America’s battery manufacturing corridor, Renforth’s assets are ideally situated to capitalize on emerging resource trends.

Conclusion: Value Waiting to Be Realized

Despite world-class assets, infrastructure, and jurisdictional advantages, Brewster noted that capital has been hard to come by for juniors — and that Renforth has instead prioritized drilling and science over promotional spending. “We’ve outlined real metals in the ground that aren’t going anywhere. What we’re building is real,” she said.

With a new gold resource estimate imminent, growing strategic relevance in the critical minerals space, and near-term catalysts ahead, Renforth Resources appears to be an underappreciated player in a district that continues to deliver major value.

For those seeking exposure to gold and critical minerals in one of the most mining-friendly regions in the world, Renforth may be one to watch.

Watch the full interview here: 

Gold Hits Record Highs Above $3100/Oz — 7 Companies Positioned to Benefit from the Boom

Posted by AGORACOM-JC at 3:09 PM on Monday, March 31st, 2025

GFG logo served with static path of public directory

Gold prices have recently reached new record highs, continuing an impressive upward trajectory that began during Donald Trump’s presidency. Since January 20, the precious metal has gained approximately 15%, marking a significant rally that has caught the attention of investors worldwide.

In 2024 alone, gold prices surged by 27%, and the first few months of 2025 have already seen an additional 19% increase. This remarkable climb follows Trump’s announcement of new trade tariffs, which set the stage for economic uncertainty. While many had expected targeted tariffs on certain countries, Trump surprised markets by declaring that his reciprocal tariffs would apply to “all countries,” including a 25% tariff on auto imports.

The intensifying trade tensions and global economic unpredictability have led many investors to seek refuge in safe-haven assets like gold. With the uncertainty surrounding international trade and the broader financial markets, gold has become a go-to investment for those looking to hedge against volatility.

As the price of gold continues to soar, several exploration companies are well-positioned to benefit from this upward trend. These companies are actively exploring for gold in key regions around the world, further solidifying their place in this growing market.

Featured Gold Companies:

ESGold | LinkedIn

(CSE: ESAU) (OTCQB: ESAUF) 

ESGold Corp. An imminent producer in the mining-friendly region of Quebec, is advancing rapidly toward production with a high-margin economic model, minimal capital expenditures, and a district-scale exploration opportunity. The company’s flagship Montauban property, located just 80 kilometers west of Quebec City, is fully permitted and set to achieve production within six months of securing final financing. The construction cost is estimated at just $6M CAD, with an additional $2M CAD needed for initial operating expenses, making ESGold well-positioned to enter production swiftly and efficiently.

The Preliminary Economic Assessment (PEA) for the Montauban project highlights robust financials, including projected gross revenues of CAD $106.9 million, with potential upside of over $315 million in the first five years. The PEA indicates an Internal Rate of Return (IRR) of 66.3% based solely on tailings, with a remarkable 142% IRR when factoring in near-surface high-grade hard rock ore. ESGold’s payback period is just 0.9 years, offering a rapid return on investment. In Year 1, the project is expected to generate over $23 million in cash flow at current gold and silver prices. The production plan includes an initial throughput of 500 tonnes per day (tpd), which will scale to 1,000 tpd, allowing for a 300,000-tonne annual throughput once fully optimized. ESGold has already secured key infrastructure, including a completed mill building, hydroelectric line, and the necessary equipment to start operations.

View Hub: https://agoracom.com/ir/ESGoldCorp

View Profile: https://agoracom.com/ir/ESGoldCorp/profile

Home | Green River Gold

(CSE: CCR) (OTC: CCRRF)

Green River Gold Corp. is actively advancing its gold initiatives in British Columbia’s prolific Cariboo Mining District—one of Canada’s most historically productive gold regions. The company is currently generating near-term cash flow through placer gold mining operations on the Swift River at its Wabi Claim, where it has access to 200 square kilometers of gold-prospective property. This operation complements its exploration efforts at the 100%-owned Fontaine Gold Project, strategically located adjacent to Osisko Development’s Cariboo Gold Project. The Fontaine Project benefits from significant historical data and regional geological continuity, making it a high-priority exploration target for hard rock gold potential.

In 2024, Green River began a deep drilling program at the Fontaine property and intersected elevated gold mineralization, marking a promising step toward identifying a potentially significant gold system. The company also owns a full-service facility in Quesnel that supports both in-house operations and regional prospectors, giving it a unique infrastructure advantage. With cash flow from placer mining, strategic land positioning, and growing exploration upside, Green River Gold is carving out a differentiated position in the junior gold sector.

View Hub: https://agoracom.com/ir/GreenRiverGoldCorp

View Profile: https://agoracom.com/ir/GreenRiverGoldCorp/profile

Profile for Great Atlantic Resources Corp. (GR.v)

(TSXV: GR)

Great Atlantic Resources is a Canadian exploration company focused on uncovering high-potential gold assets within Atlantic Canada, particularly in Newfoundland. Its flagship asset, the Golden Promise Gold Property, is located in central Newfoundland and hosts multiple gold-bearing quartz veins. The most notable of these is the Jaclyn Main Zone for which a NI 43-101 inferred resource estimate details 357,500 tonnes at an average grade of 10.4 grams per tonne (g/t) gold, totaling approximately 119,900 ounces of uncapped gold. ​

View Hub: https://agoracom.com/ir/GreatAtlanticResources

View Profile: https://agoracom.com/ir/GreatAtlanticResources/profile

Home - Lancaster Resources Inc.

(CSE:LCR) (OTCQB:LANRF)

Lancaster Resources Inc. is a Canadian exploration company focused on critical minerals essential for electrification and decarbonization. Among its assets, the Piney Lake Gold Property stands out. Spanning 2,267.8 hectares in Saskatchewan, about 65 km east of La Ronge Provincial Park, it is surrounded by SGO/SSR Mining’s prolific gold claims—placing it in a region with a strong history of discoveries.

Historical geochemical sampling has identified promising gold showings along a north-south trend, including 7.55 g/t gold about 375 meters north of the property and 41.35 g/t gold approximately 4.1 km to the north. These findings highlight Piney Lake’s exploration potential. With strategic positioning and strong historical data, Lancaster Resources is advancing its exploration efforts, reinforcing its role in the evolving energy landscape.

View Hub: https://agoracom.com/ir/Lancasterresources

View Profile: https://agoracom.com/ir/Lancasterresources/profile

Lake Winn Resources Corp. | Lithium Exploration Company

(LWR: TSXV)

Lake Winn Resources Corp. is a Canadian mineral exploration company focused on advancing its gold projects in Manitoba’s Flin Flon Gold Belt. Its flagship Cloud Project, 40 km northeast of Flin Flon, has delivered high-grade drill results, including 1m at 17.3 g/t gold and 1m at 10.2 g/t gold.

The company’s Quartz Project, 76 km southeast of Flin Flon, hosts historical high-grade intercepts, with reports of up to 19.9 g/t gold. Lake Winn has secured permits for access and drilling, reinforcing its commitment to exploration in this prolific mining region.

With projects in historically productive areas and strong early results, Lake Winn Resources is well-positioned in Canada’s gold exploration sector.

View Hub: https://agoracom.com/ir/LakeWinnResources

View Profile: https://agoracom.com/ir/LakeWinnResources/profile

Loncor Gold Announces Sale of Makapela Property for CDN$13,500,000

(TSX: LN) (OTCQX: LONCF)

Loncor Gold Inc. is a Canadian gold exploration company focused on the Ngayu Greenstone Belt in the Democratic Republic of the Congo (DRC). Its flagship Adumbi deposit hosts an estimated 3.66 million ounces of gold, with 1.88 million ounces categorized as indicated and 1.78 million ounces as inferred resources, making it the second-largest deposit in the DRC. Based on current gold prices, the project’s net present value (NPV) is estimated at approximately $2 billion post-tax.

Strategically located near Africa’s largest gold mine, the Barrick Gold-managed Kibali mine, Adumbi benefits from established infrastructure and industry expertise. Loncor’s goal is to elevate Adumbi to a Tier 1 asset by surpassing the 5-million-ounce resource threshold, positioning the company as a key player in the DRC’s gold mining sector.

View Hub: https://agoracom.com/ir/LoncorGold

View Profile: https://agoracom.com/ir/LoncorGold/profile

Front Page - Renforth Resources

(CSE: RFR) (OTCQB: RFHRF)

Renforth Resources Inc. is advancing its 100%-owned Parbec Gold Deposit, strategically located beside Agnico Eagle’s Canadian Malartic Mine—the largest open-pit gold mine in Canada—within Quebec’s Abitibi Greenstone Belt. The company is updating its geological model and preparing a new NI 43-101 resource estimate incorporating 15,000 metres of drilling since late 2019, along with previously excluded historical data, significantly enhancing Parbec’s scale and definition.

Renforth is also optimizing development strategies, including dewatering an underground decline for bulk sampling and detailed mapping. Additionally, the company plans to implement TOMRA sorting technology to pre-concentrate mineralized material, reducing waste and improving processing efficiency. With strong infrastructure access and strategic positioning, Renforth is well-placed to unlock Parbec’s full potential and expand its footprint in gold exploration.

View Hub: https://agoracom.com/ir/RenforthResources

View Profile: https://agoracom.com/ir/RenforthResources/profile

 

Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 9:54 AM on Thursday, March 27th, 2025

New Approach Could Redefine How Multiple Sclerosis Is Treated Worldwide

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) may be on the verge of redefining treatment for multiple sclerosis (MS), a chronic neurological disorder affecting nearly 3 million people worldwide. In a compelling interview on the AGORACOM, Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, detailed the company’s successful completion of its Phase 1 clinical trial for Lucid-MS, a first-in-class neuroprotective drug targeting demyelination—the core driver of MS progression.

Unlike existing treatments, which primarily focus on managing the immune system and controlling inflammation, Lucid-MS takes aim at protecting and potentially repairing the myelin sheath—the protective layer around nerve cells that degenerates in MS patients. “We’re excited about the potential of Lucid-MS to protect myelin in MS patients as it represents a new direction in the treatment of this disease,” said Quantum BioPharma CEO Zeeshan Saeed.

A Novel Solution to a Persistent Problem

Most MS therapies today only address the inflammatory aspect of the disease, leaving the underlying neurodegeneration largely unaddressed. Lucid-MS changes that narrative.

  • The drug works by preventing the unraveling of the myelin sheath, a process triggered by a chemical modification known as citrullination.

  • Developed over a decade by Dr. Lakshmi Kotra and Dr. Mario Moscarello at the University of Toronto, Lucid-MS targets this key process, aiming to halt disease progression and protect nerve communication.

  • The approach has already shown success in preclinical animal models.

“Think of the myelin sheath like insulation around electrical wiring. When that’s compromised, signals can’t transmit properly,” explained Dr. Chruscinski. “Our drug preserves that insulation, maintaining neural function.”

Phase 1 Trial: Safety Confirmed, Therapeutic Potential Emerges

The recently completed Phase 1 trial focused on evaluating safety and pharmacokinetics in healthy participants. According to Dr. Chruscinski, “Lucid-MS was safe and well-tolerated, with no adverse events. We’re also pleased with the drug levels observed in blood, which we believe are therapeutic.”

This milestone is crucial for advancing to Phase 2, where the company will begin testing Lucid-MS in MS patients to assess efficacy.

What to Expect in Phase 2

The company is actively designing its Phase 2 trial with a projected start in Q1 2026, pending FDA clearance via an Investigational New Drug (IND) application in late 2025.

Key details under consideration:

  • The trial will include roughly 60 MS patients (30 receiving Lucid-MS and 30 on placebo).

  • Outcomes will be measured using MRI scans and clinical assessments to evaluate both biological and functional improvement.

  • While the exact location is yet to be confirmed, Quantum is exploring options to include Canadian sites in recognition of the drug’s Canadian origins.

Support From the Scientific Community

Feedback from global experts at major MS conferences in North America and Europe has been overwhelmingly positive. “The response has been tremendous,” said Dr. Chruscinski. “There’s a real appetite for a drug that targets neurodegeneration, which remains an unmet need in MS.”

This third-party validation underscores the broader scientific and commercial relevance of Quantum BioPharma’s work.

A Human-Centered Mission With Investor Appeal

Dr. Chruscinski also emphasized his personal motivation. “It’s exciting to be part of something that could make a real difference. I was there when the first dose was administered in our Phase 1 trial. That’s a moment I won’t forget.”

While the drug development process remains long and complex, Quantum BioPharma has achieved a significant milestone that positions the company—and Lucid-MS—at the forefront of innovation in MS treatment.

For investors, the opportunity lies in Quantum’s unique approach, successful early data, and a clearly defined path toward a potential market-shifting solution.

Conclusion: A Meaningful Milestone With a Promising Horizon

With a Phase 1 trial successfully completed and a novel therapeutic mechanism unlike anything currently on the market, Quantum BioPharma is emerging as a company to watch in the fight against multiple sclerosis. As it gears up for its Phase 2 trial and FDA engagement, the company stands at a pivotal inflection point—one that could not only deliver long-term value for investors but also reshape the future of MS care.

To hear Dr. Chruscinski explain the science, milestones, and next steps in his own words, watch the full interview here: 

Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 5:01 PM on Tuesday, March 25th, 2025

KEY MILESTONES AND WHAT’S NEXT

  • Successful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.
  • Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.
  • FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.
  • Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding space.

A NEW ERA IN MULTIPLE SCLEROSIS TREATMENT

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Lucid-MS is setting the stage to revolutionize MS treatment. Unlike existing therapies that only target immune system responses, Lucid-MS focuses on protecting and repairing myelin, the critical layer around nerve fibers. This novel approach has the potential to slow or even reverse disease progression—offering new hope for millions of MS sufferers.

HOW DOES IT WORK? A TOTALLY NEW APPROACH TO TREATING MS

Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

WHY IS THIS IMPORTANT?

By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.

SCIENTIFIC BREAKTHROUGH BACKED BY INDUSTRY RECOGNITION

Lucid-MS is backed by cutting-edge research from Dr. Lakshmi Khotra’s lab at the University of Toronto, where the critical process of myelin breakdown in MS patients was discovered. The drug’s ability to address this underlying issue is a potential game-changer in neurodegenerative treatments.

It’s already gaining enthusiastic support from leading medical experts and researchers, underscoring its transformative potential.

A VISION FOR THE FUTURE

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the company’s excitement about Lucid-MS’s future.

“We are on the cusp of something monumental. Lucid-MS has the potential to transform MS treatment and open doors for treating other nerve-related diseases. As we move toward Phase 2 and beyond, we’re excited to bring this innovative therapy to the patients who need it most.”

With promising clinical results, a massive market opportunity, and rising industry recognition, Quantum BioPharma is leading the charge in next-generation treatments for Multiple Sclerosis 

YOUR NEXT $QNTM STEPS

$QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopha… $QNTM Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Quantumbiopha… Connect With AGORACOM Anyway You Like AGORACOM Website: https://www.agoracom.com – The Most Trusted Source Of Small Cap Information AGORACOM YouTube: Hit That Subscribe Button Right Now For More Powerful Videos AGORACOM X: https://www.x.com/AGORACOM Verified Top 0.2% Account AGORACOM Spotify: https://open.spotify.com/show/74mVPkf… Planes, Trains, Automobiles & Walking The Dog AGORACOM

3 Billion Gamers, $21B Market—Why Kidoz Is Winning in Mobile AdTech

Posted by Brittany McNabb at 4:16 PM on Tuesday, March 25th, 2025

In the ever-evolving world of entertainment, gaming is no longer just a pastime—it’s the most powerful and profitable media format in the world. Surpassing film, music, and television, mobile gaming has emerged as the dominant platform for engagement, particularly among younger audiences. At the center of this transformation is Kidoz Inc. (TSXV:KIDZ), a mobile AdTech leader specializing in safe, COPPA- and GDPR-compliant digital advertising for kids and families.

As brands shift their media strategies toward platforms that guarantee attention, interaction, and safety, Kidoz is proving to be a high-performing partner in the mobile gaming ecosystem.

Gaming: The Modern Entertainment Powerhouse

Over the past decade, gaming has gone from niche to mainstream. With over 3 billion active players globally, gaming now generates more revenue than film and music combined. It’s more immersive, more social, and more accessible than ever, thanks to the ubiquity of smartphones and tablets. And while older generations still turn to traditional media, younger audiences—especially Gen Alpha and Gen Z—are spending more time gaming than on any other media platform.

This is where Kidoz thrives.

Operating within this high-growth market, Kidoz enables brands to reach young audiences where they spend their time—inside games and apps—without compromising safety or privacy. With the Kidoz Contextual Ad Network, advertisers can deliver age-appropriate, engaging content across thousands of kid-focused mobile platforms, video channels, and websites.

Record-Breaking Revenue in Q4 2024

Kidoz’s latest financial performance underscores the value of its position in the gaming-driven ad market. In Q4 2024, Kidoz reported record revenue of USD $7.44 million, marking a +23% year-over-year increase and a +225% gain over Q3 2024. The company also delivered a pre-tax profit of $2.2 million, reversing a loss from the prior quarter.

Other financial milestones include:

  • Adjusted EBITDA: $2.17 million (up from $591K in Q4 2023) 
  • Free Cash Flow: $2.34 million (vs. $37.8K in Q4 2023) 
  • Cash Reserves: $2.78 million at year-end 2024 

This performance is being driven by greater direct brand investment, increased adoption of Kidoz’s programmatic ad solutions, and strong platform optimization—making the company a standout in an increasingly crowded space.

Tapping into Gen Alpha with Contextual Precision

Gen Alpha is growing up in a world where gaming is not just entertainment—it’s culture. Mobile games are where they watch videos, socialize with friends, and engage with content. Unlike previous generations, Gen Alpha is mobile-first by default.

Kidoz’s technology ensures brands can reach this audience in a compliant, respectful, and meaningful way. The platform leverages AI-powered contextual targeting to ensure that ads are relevant, safe, and delivered in the right environment—without relying on personal data or intrusive tracking methods.

This makes Kidoz a go-to solution for brands like LEGO, Mattel, Disney, and Kraft, all of whom have launched campaigns through the Kidoz network to engage young users effectively and ethically.

The Future of AdTech Is Kid-Safe, High-Performance, and Global

Looking ahead to 2025 and beyond, Kidoz is expanding its global footprint through direct brand relationships and strategic event participation. With industry-leading tools like the Kidoz Publisher SDK and Kidoz COPPA Shield, the company continues to raise the standard for what’s possible in mobile advertising.

With the kids’ digital advertising market projected to surpass $21 billion by 2031, and regulatory changes like COPPA 2.0 expected to expand the total addressable market, Kidoz is not only riding the wave—it’s helping to shape it.

As gaming cements itself as the entertainment format of the future, Kidoz is uniquely positioned to be the platform that connects the world’s most trusted brands with the next generation of digital consumers—securely, effectively, and at scale.

Source: https://www.kidoz.net/blog/gaming-reigns-supreme-the-entertainment-industrys-powerhouse

YOUR NEXT STEPS 

 

Visit $KIDZ HUB On AGORACOM:http:// https://agoracom.com/ir/Kidoz

Visit $KIDZ 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Kidoz/profile

Visit $KIDZ Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Kidoz/forums/discussion

Watch $KIDZ Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

 

For our full website disclaimer, please visithttp://  https://agoracom.com/terms-and-conditions

Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

Posted by Brittany McNabb at 1:18 PM on Monday, March 24th, 2025

Key Takeaway for Investors:
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 clinical trial for Lucid-21-302 (Lucid-MS), an experimental drug for multiple sclerosis (MS). The drug was found to be safe and well-tolerated, paving the way for the next phase of clinical testing.

What Happened?
The company conducted a Phase 1 trial to test the safety of Lucid-MS in healthy volunteers. The study followed strict protocols, including a final review by a Safety Review Committee, which confirmed there were no safety concerns or serious side effects.

Why This Matters:
Lucid-MS is a first-of-its-kind drug designed to protect the myelin sheath around nerve fibers, which is damaged in MS patients. Unlike existing MS treatments, which primarily focus on the immune system, Lucid-MS directly works to stabilize myelin, potentially slowing disease progression.

Next Steps:
With safety confirmed, Quantum BioPharma now plans to move forward with a Phase 2 trial, which will test Lucid-MS in MS patients to evaluate its effectiveness in treating the disease.

CEO Statement:
Zeeshan Saeed, CEO of Quantum BioPharma, emphasized the significance of this milestone, stating that the company is now closer to making a breakthrough treatment for MS patients a reality.

Investor Outlook:
The successful completion of Phase 1 is a major step toward potential drug approval and commercialization. Investors should keep an eye on upcoming Phase 2 trial developments, as positive results could significantly increase the drug’s market potential.

What Does Lucid-21-302 Do? (In Simple Terms)

Lucid-21-302 (Lucid-MS) is a new experimental drug designed to protect nerve fibers in people with multiple sclerosis (MS).

How Does It Work?
Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. In MS, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

Why Is This Important?
By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.
If future trials confirm its effectiveness, it could be a game-changer for people living with MS.

Source: https://agoracom.com/ir/Quantumbiopharma/forums/discussion/topics/808536-Quantum-BioPharma-Advances-Multiple-Sclerosis-Drug-with-Successful-Phase-1-Trial-Completion-A-Milestone-in-MS-Treatment-Development/messages/2432086